Composite magnetic nanoparticle drug delivery system

{
  "publication_number": "US9782342B2",
  "country": "US",
  "kind": "B2",
  "title": "Composite magnetic nanoparticle drug delivery system",
  "abstract": "A composite magnetic nanoparticle drug delivery system provides targeted controlled release chemotherapies for cancerous tumors and inflammatory diseases. The magnetic nanoparticle includes a biocompatible and biodegradable polymer, a magnetic nanoparticle, the biological targeting agent human serum albumin, and a therapeutic pharmaceutical composition. The composite nanoparticles are prepared by oil-in-oil emulsion/solvent evaporation and high shear mixing. An externally applied magnetic field draws the magnetic nanoparticles to affected areas. The biological targeting agent draws the nanoparticles into the affected tissues. Polymer degradation provides controlled time release delivery of the pharmaceutical agent.",
  "claims": [
    "1. A method of localized therapy including the steps of: providing a quantity of composite nanoparticles comprising a synthetic resin polymer composition, magnetic nanoparticles, a biological targeting component that draws the composite nanoparticles into tissue, and a pharmaceutical composition, positioning magnets adjacent an area of a patient to be treated, delivering a quantity of the composite nanoparticles into the body of the patient, and magnetically drawing the composite nanoparticles to the affected area, wherein said biological targeting component that draws the composite nanoparticles into tissue is albumin.",
    "2. The method of localized therapy of claim 1, wherein a quantity of 10 4 to 10 5 composite magnetic nanoparticles is delivered into the body of a patient by injection into the bloodstream.",
    "3. The method of claim 1, wherein the amount of biological targeting component that draws the composite nanoparticles into tissue in the composite nanoparticles comprises from about 5% to about 85% (v/v).",
    "4. The method of claim 3, wherein said synthetic resin polymer is biodegradable.",
    "5. The method of claim 3, wherein said synthetic resin polymer is selected from the group consisting of poly(lactic-co-glycolic acid) or poly(D,L-lactide-co-glycolide) (or PLGA), chitosan, poly(lactic acid) (or PLA), poly(glycolic acid) (or PGA), polycaprolactone (or PCL), and combinations thereof.",
    "6. The method of claim 5, wherein said synthetic resin polymer is PLGA.",
    "7. The method of claim 6, wherein said PLGA is made up of monomers and each monomer is present in an amount ranging from 15% to about 85%.",
    "8. The method of claim 1, wherein said composite nanoparticles include from about 5% to about 95% (w/v) of said synthetic resin polymer.",
    "9. The method of claim 1, wherein said pharmaceutical composition is selected from the group consisting of anti-rheumatic agents (DMARDs), anti-inflammatory agents, anti-malarial medications, biological response modifiers, corticosteroids, cyclooxygenase-2 (COX-2) inhibitors, methotrexate, 5-Fluorouracil, doxorubicin, epirubicin, cyclophosphamide, docetaxel, doxorobicin, paclitaxel, cisplatin, and combinations thereof.",
    "10. The method of claim 1, wherein said magnetic nanoparticle is selected from the group consisting of magnetite and cobalt ferrite.",
    "11. The method of claim 1, wherein said composite magnetic nanoparticles include from about 0.5% to about 50% of said magnetic nanoparticles.",
    "12. The method of claim 1, wherein said magnetic nanoparticles have a diameter of from about 5 nm to about 20 nm.",
    "13. The method of claim 1, wherein said composite nanoparticle has an average diameter from about 40 nm to about 1.1 μm.",
    "14. A method of localized therapy including the steps of: providing a quantity of composite nanoparticles comprising a biodegradable synthetic resin polymer composition selected from the group consisting of poly(lactic-co-glycolic acid) or poly(D,L-lactide-co-glycolide) (or PLGA), chitosan, poly(lactic acid) (or PLA), poly(glycolic acid) (or PGA), polycaprolactone (or PCL), and combinations thereof, magnetic nanoparticles, a biological targeting component that draws the composite nanoparticles into tissue, and a pharmaceutical composition, positioning magnets adjacent an area of a patient to be treated, delivering a quantity of the composite nanoparticles into the body of the patient, and magnetically drawing the composite nanoparticles to the affected area, wherein said biological targeting component that draws the composite nanoparticles into tissue is albumin.",
    "15. The method of claim 14, wherein the amount of albumin in the composite nanoparticles comprises from about 5% to about 85% (v/v).",
    "16. The method of claim 14, wherein said biodegradable synthetic resin polymer is PLGA.",
    "17. The method of claim 14, wherein said pharmaceutical composition is selected from the group consisting of anti-rheumatic agents (DMARDs), anti-inflammatory agents, anti-malarial medications, biological response modifiers, corticosteroids, cyclooxygenase-2 (COX-2) inhibitors, methotrexate, 5-Fluorouracil, doxorubicin, epirubicin, cyclophosphamide, docetaxel, doxorobicin, paclitaxel, cisplatin, and combinations thereof.",
    "18. The method of claim 14, wherein said magnetic nanoparticle is selected from the group consisting of magnetite and cobalt ferrite.",
    "19. The method of claim 14, wherein said composite magnetic nanoparticles include from about 0.5% to about 50% of said magnetic nanoparticles.",
    "20. The method of claim 14, wherein said magnetic nanoparticles have a diameter of from about 5 nm to about 20 nm.",
    "21. The method of claim 14, wherein said composite nanoparticle has an average diameter from about 40 nm to about 1.1 μm.",
    "22. The method of claim 14, wherein a quantity of 10 4 to 10 5 composite magnetic nanoparticles is delivered into the body of a patient by injection into the bloodstream.",
    "23. The method of claim 16, wherein said PLGA is made up of monomers and each monomer is present in an amount ranging from 15% to about 85%.",
    "24. The method of claim 14, wherein said composite nanoparticles include from about 5% to about 95% (w/v) of said biodegradable synthetic resin polymer."
  ],
  "description_excerpt": "The present disclosure is broadly concerned with drug delivery systems. More particularly, it is concerned with drug carrying nanocomposite particles including magnetic nanoparticles and a biocompatible polymer that is biodegradable.\n\nConventional chemotherapies for cancers and inflammatory diseases act systemically, causing severe side effects throughout a patient's body. The cytotoxic effects are diffuse, and extend to healthy cells as well as malignant or inflamed cells. These chemotherapies also lack the ability to boost uptake of their therapeutic agents into the affected tissues, where it can be most effective. Known chemotherapies are also unable to provide slow-release delivery of pharmaceutical agents to targeted sites such as tumors and areas of inflammation.\n\nPrimary bone cancers, including osteosarcoma, chondrosarcoma, and Ewing's sarcoma, are highly malignant tumors derived from osteogenic cells or chondrocytes. Osteosarcoma is one of the most common primary malignant tumors seen in orthopedic surgery, with high mobility in young adults and adolescents. Despite intensive treatment, including adjuvant chemotherapy to localize the tumor before surgery and prevent recurrence and metastasis after surgery, wide excision of tumors, and amputation of diseased limbs, approximately half of the patients die within five years. Other cancers, such as breast, skin, liver, lung, prostate, throat and kidney, could also benefit from close targeting of chemotherapy.",
  "cpc": [
    "A61K 9/0009",
    "A61K 9/5031",
    "A61K 9/5094",
    "A61P 29/00",
    "A61P 35/00"
  ],
  "ipc": [
    "A61K 31/513",
    "A61K 31/519",
    "A61K 47/34",
    "A61K 9/14",
    "A61N 2/10",
    "A61P 29/00",
    "A61P 35/00",
    "A61K 33/24",
    "A61K 9/00",
    "A61K 9/50",
    "A61M 37/00"
  ],
  "assignees": [
    "Wichita State University"
  ],
  "inventors": [
    "Ramazan Asmatulu",
    "Heath Misak",
    "Shang-you Yang",
    "Paul Wooley"
  ],
  "filing_date": "2011-10-11",
  "publication_date": "2017-10-10",
  "grant_date": "2017-10-10",
  "priority_date": "2010-10-11",
  "application_number": "US-201113271172-A",
  "family_id": "45938683",
  "cited_by_count": 4,
  "citations": [
    "US20080160095A1",
    "US5565215A",
    "US20060041182A1",
    "US20070264199A1",
    "US20090291139A1"
  ]
}